A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT04670679

Sponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

90actual

Sites

Countries

Australia, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-12-15

actual

When the study began enrolling

Primary completion

2026-02-01

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2026

estimated

The whole study's end, after follow-up

First posted

2020-12-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-25

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced or Metastatic Solid Tumors

Interventions

Drug: ERAS-601
Drug: Cetuximab — also filed as Erbitux
Drug: Pembrolizumab — also filed as Keytruda